Hecla Closes Casa Berardi Sale, Executing Planned Divestiture Amid High Valuation Risks

What happened

Hecla Mining has completed the sale of its Casa Berardi mine to Orezone Gold, as announced today, meeting the Q1 2026 timeline highlighted in the DeepValue report. This divestiture was a critical near-term catalyst for the company's portfolio simplification strategy, aimed at focusing on North American silver assets. The DeepValue report rated HL a POTENTIAL SELL due to elevated valuation multiples after a 252% run-up, with the sale's closure expected to decrease the thesis if executed as planned. However, the stock remains richly valued at 34.7x P/E and 52.1x EV/EBITDA, pricing in flawless delivery of 2026 guidance that includes lower silver production and higher costs. With this uncertainty removed, investor attention must now shift to operational execution, particularly Greens Creek's output and by-product credit sensitivity, which are essential to sustaining the low-cost narrative.

Implication

Hecla's completion of the Casa Berardi sale reinforces its strategic pivot to a silver-focused portfolio, reducing complexity and execution risk from the divestiture. This allows investors to better assess core operations, but the high valuation multiples imply no margin of safety, making quarterly production and cost reports critical for sentiment. By-product credits, which drive reported low costs, remain highly sensitive to gold, zinc, and lead prices, adding external volatility that could erode margins if prices weaken. The sale's success shifts the burden to operational metrics like Greens Creek's silver output, which must meet guidance to justify current prices. Therefore, while the divestiture progress is positive, it does not mitigate the fundamental need for perfect execution to avoid a significant downside repricing.

Thesis delta

The closure of the Casa Berardi sale was a key condition for decreasing the POTENTIAL SELL thesis, as it removes the execution risk associated with this divestiture. This event shifts the thesis slightly towards a more neutral stance, but core concerns—high valuation, dependency on by-product credits, and operational delivery risks—persist unchanged. Investors should now focus on upcoming production and cost data to reassess whether the stock's premium is warranted.